Clinical trial NCT03446209: Tocilizumab for the Treatment of Familial Mediterranean Fever
Official title: Tocilizumab for the Treatment of Familial Mediterranean Fever - A Randomized, Doubleblind, Phase II Proof of Concept Study
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: PHASE2
Conditions: Familial Mediterranean Fever
Lead sponsor: University Hospital Tuebingen
Sponsor class: OTHER
First posted: 2018-02-26
Enrollment: 30
Sex: ALL
Minimum age (years): 18
Maximum age (years): 64
Standard ages: ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Intervention model description: Multi-center, phase II, randomized, placebo-controlled, double blind proof of concept trial
Primary purpose: TREATMENT

Brief summary: Adult patients with Familial Mediterranean Fever, who have active disease

Detailed description: FMF is a rare disease, which permanently affects daily life of the patients with severe pain and the risk of developing a life threatening amyloidosis. Today there are only very limited treatment options and an ongoing highly unmet medical need for improved treatment strategies. This study will be the first randomized, controlled trial to assess the benefit as well as the safety profile of IL6 receptor inhibition wirth TCZ in patients with FMF. Elevated tissue and serum levels of IL-6 have been implicated in the pathogenesis of FMF. FMF attacks are painfull during the period of the attack but are not life- or organthreatening and usually can be handeled by nonsteroidal and antipyretic treatment. Amyloidos is a longtime complication that appears after several years of uncontrolled disease. Placebo control trials' data are characterized as having greater ability to distinguish between effective and ineffective treatments (that is, greater assay sensitivity). The concerns about placebo use should revolve around the issue of risk to participants, rather than around denial of treatment, and that in the absence of a significant risk of harm, placebo treatment is acceptable. In general, it is easier to achieve statistical significance in placebo-controlled trials, where effects tend to be larger, such that smaller numbers of participants need to be exposed to the investigational medication (and research costs are lower.) This is especially important in rare diseases like FMF. If an active control was itself never evaluated in a placebo-controlled trial, using it in an equivalency study, begs the question of its efficacy. This is the case for Canakinumab as a potential active comparator in FMF. No randomized controlled trial is published for this indication by now. Therefore, a placebo controlled study over a period of 16 weeks seems to be justifiable without exposing our patients to risk of serious or irreversible harm. NSAR and antipyretic treatment, as a rescue therapy for attacks, is possible throughout the study. In addition, all patients with uncontrolled active disease despite NSAR or paracetamol will drop out and will be treated with escape therapy, especially Canakinumab. Based on the available safety data in the RA program, the adverse effects of TCZ have been shown to be manageable (e.g. cytopenia, liver encyme elevation), reversible and usually not treatment limiting . The safety profile and tolerability of TCZ are expected to be similar or even better in patients with FMF than in patients with rheumatoid arthritis or giant cell arteritis, as the cohort of FMF patients is, in general, younger and shows less concomitant diaseases. Overall, the benefit-risk ratio of FMF patients to be treated with TCZ is judged positive.

Eligibility criteria: Inclusion Criteria:

* Age ≥ 18 years and written informed consent
* FMF according to the Tel Hashomer Criteria; with at least one heterozygous or homozygous mutation of the MEFV gene
* Inadequate response or intolerance to colchicine (inadequate response/intolerance:

disease activity despite colchicine with at least 2 x 0.5 mg/day or intolerance to colchicine)

* Attack during the last 12 weeks, defined as episodes of fever and/or pericarditis and/or serositis and/or testis involvement and/or arthritis and/or erysipelas-like rash and

  * CRP \> 0.5 mg/dl and/or ESR \> 20mm/h and/or SAA \> 10mg/dl
  * PGA \>2
* Understand and voluntarily sign an informed consent document prior to any study related assessments/procedures.
* Ability to adhere to the study visit schedule and other protocol requirements.
* Females of childbearing potential (FCBP\*) must agree to utilize two reliable forms of contraception simultaneously from heterosexual contact for at least 28 days before starting study drug, while participating in the study (including dose interruptions), and for 6 months after study treatment discontinuation and must agree to regular pregnancy testing during this timeframe to abstain from breastfeeding during study participation and 6 months after study drug discontinuation.
* Males must agree to use a latex condom during any sexual contact with FCBP while participating in the study and for 6 months following discontinuation from this study, even if he has undergone a successful vasectomy to refrain from donating semen or sperm while on Tocilizumab/Placebo and 6 months after discontinuation from this study treatment.
* All subjects must agree to refrain from donating blood while on study drug and 6 months after discontinuation from this study treatment.
* All subjects must agree not to share medication.

A female of childbearing potential is a sexually mature woman who: 1) has not undergone a hysterectomy or bilateral oophorectomy; or 2) has not been naturally postmenopausal for at least 24 consecutive months (i.e., who has had menses at any time in the preceding 24 consecutive months).

Exclusion Criteria:

Subjects presenting with any of the following criteria will not be included in the trial:

* Patient participating simultaneously in other clinical interventional trials
* Major surgery within 8 weeks prior to screening or planned major surgery within 12 months after randomization
* Transplanted organs (except corneal transplant performed more than 3 months prior to screening)

Exclusions Related to Prior or Concomitant Therapy

* Previous treatment with TCZ
* Treatment with glucocorticosteroids \>10mg/day within 1 week; prednisolone ≤ 10mg/day can be given on a stable dose throughout the study
* Analgesic medication, other than paracetamol or ibuprofen or diclofenac or colchicine, which can be used at a stable dose throughout the study and/or for treatment of FMF attacks to the maximum allowed daily dose (paracetamol: 4000mg/day, ibuprofene: maximum 2400mg/day, diclofenac maximum 150mg/day; colchicine 12mg/day) .
* Treatment with any investigational agent within 12 weeks (or 5 half-lives of the investigational drug, whichever is longer) of screening
* Treatment with Anakinra within the last 1 week prior to baseline (ptb), Canakinumab within the last 8 week prior to baseline
* Treatment with etanercept within 2 weeks; certolizumab pegol, abatacept or adalimumab within 6 weeks; golimumab and infliximab within 8 weeks ptb
* Rituximab within 24 weeks ptb
* Leflunomide within 12 weeks ptb (washout possible),
* azathioprine, cyclophosphamide within 12 weeks ptb
* Immunization with a live/attenuated vaccine within ≤ 4 weeks ptb
* Previous treatment with cell-depleting therapies, including investigational agents or approved therapies: anti-CD33, anti-CD52, anti-CD4, anti-CD5, anti- CD3 and anti-CD19
* Treatment with intravenous gamma globulin within 6 months of baseline
* Treatment with plasmapheresis within 6 months of baseline
* Any previous treatment with alkylating agents such as chlorambucil, or with total lymphoid irradiation

Exclusions Related to General Safety

* History of severe allergic or anaphylactic reactions to human, humanized, or murine antibodies
* Evidence of serious uncontrolled concomitant cardiovascular, nervous system, pulmonary (including obstructive pulmonary disease), renal, hepatic, psychiatric or gastrointestinal (GI) disease
* History of diverticulitis, diverticulosis requiring antibiotic treatment, or chronic ulcerative lower GI disease such as Crohn's disease, ulcerative colitis, or other symptomatic lower GI conditions that might predispose a patient to perforations
* Known active current or history of recurrent bacterial, viral, fungal, mycobacterial, or other infections (including but not limited to tuberculosis (TB) and atypical mycobacterial disease, hepatitis B and C, and herpes zoster, but excluding fungal infections of the nail beds)
* Any major episode of infection requiring hospitalization or treatment with IV antibiotics within 4 weeks of screening or oral antibiotics within 2 weeks of screening
* Active TB requiring treatment within the previous 3 years; patients should be screened for latent TB and, if positive, treated according to local practice guidelines prior to initiating TCZ treatment; patients treated for TB with no recurrence within 3 years and patients treated for latent TB within 3 years are eligible.
* Primary or secondary immunodeficiency (history of or currently active)
* Evidence of malignant disease or malignancies diagnosed within the previous 5 years (except basal and squamous cell carcinoma of the skin or carcinoma in situ of the cervix uteri that have been excised and cured)
* FCBP who are not willing to use an effective method of contraception, such as condom, sterilization during the study and for a minimum of 6 months after study drug therapy and breast-feeding females
* Pregnant women
* Males of reproductive potential who are not willing to use an effective method of contraception, such as condom, sterilization, or true abstinence throughout study and for a minimum of 6 months after study drug therapy
* History of alcohol, drug, or chemical abuse within 1 year prior to screening

Laboratory Exclusions (at Screening)

* Serum creatinine \>1.4 mg/dL in female patients and \>1.6 mg/dL (in male patients
* ALT or AST \> 2 ×ULN
* Total bilirubin \> 2 x ULN
* Platelet count \< 100 × 109/L
* Hemoglobin \< 8.5 g/dL
* White blood cells \< 3.0 ×109/L
* Absolute neutrophil count \< 2.0 × 109/L
* Absolute lymphocyte count \< 0.5 × 109/L
* Positive hepatitis B surface antigen, anti-HBc, HIV or hepatitis C antibody

Primary outcomes:
measure: Efficacy: measured change of Physician's Global Assessment of disease activity (PGA)
timeFrame: at week -4,0,4,8,12,16,20,24,28,32
Secondary outcomes:
measure: Incidence of Treatment-Emergent Adverse Events-Determination of Erytthro Sedimentation Rate (ESR)
timeFrame: at week -4,0,4,8,12,16,20,24,28,32
measure: serological remission
timeFrame: at week 16, 28
measure: SAA level
timeFrame: at week 16 + 28
Other outcomes:
measure: Incidence of Treatment-Emergent Adverse Events -Determination of the C-reactive protein
timeFrame: at week -4,0,4,8,12,16,20,24,28,32
measure: Incidence of Treatment-Emergent Adverse Events -Determination of the blood cell count
timeFrame: at week -4,0,4,8,12,16,20,24,28,32
measure: Incidence of Treatment-Emergent Adverse Events -Determination of serum parameters (Creatinine)
timeFrame: at week -4,0,4,8,12,16,20,24,28,32
measure: Incidence of Treatment-Emergent Adverse Events -Determination of renal parameters (Uric Acid)
timeFrame: at week -4,0,4,8,12,16,20,24,28,32
measure: Incidence of Treatment-Emergent Adverse Events -Determination of serum and renal parameters (Glomerular Filtration Rate)
timeFrame: at week -4,0,4,8,12,16,20,24,28,32
measure: Incidence of Treatment-Emergent Adverse Events -Determination of liver parameters (Gamma Glutamyltransferase (GGT))
timeFrame: at week -4,0,4,8,12,16,20,24,28,32
measure: Incidence of Treatment-Emergent Adverse Events -Determination of liver parameters ( Alanine- (ALT) -Aminotransferase)
timeFrame: at week -4,0,4,8,12,16,20,24,28,32
measure: Incidence of Treatment-Emergent Adverse Events -Determination of liver parameters ( Alanine-Aminotransferase (AST))
timeFrame: at week -4,0,4,8,12,16,20,24,28,32
measure: Incidence of Treatment-Emergent Adverse Events -Determination of liver parameters (Biliribun)
timeFrame: at week -4,0,4,8,12,16,20,24,28,32
Locations:
city: Cologne
country: Germany
facility: Universitätsklinikum Köln, Klinik I für Innere Medizin
state: NRW
city: Berlin
country: Germany
facility: Charité Universitätsmedizin Berlin, Klinik für Rheumatologie und Klinische Immunologie, Abteilung -Neue Therapien & Studien
city: Tuebingen
country: Germany
facility: University Hospital Tuebingen; Department of oncology, hematology, rheumatology, immunology and pulmology
Study officials:
References: